Abstract
The prothrombin time (PT) is the most important coagulation test. After many years of disagreement, an international system of standardisation has been accepted. Fifty years after Quick1 described the PT to detect coagulation defects, the control of oral anticoagulant therapy is still largely dependent on the test. Many modifications to the original technique have been introduced, and new methods have been developed specifically, e.g. the prothrombin and proconvertin test (P and P test),2 and the Throm-botest,3 but their application has been limited in comparison. Clinical reports of anticoagulant trials, giving no details of the PT method are still published.(e,g.4)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. J. Quick, The prothrombin in haemophilia and in obstructive jaundice, J. Biol. Chem. 109:73–74 (1935).
P. A. Owren and K. Aas, The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin, Scand. J. Clin. Lab. Invest. 3:201–208 (1951).
P.A. Owren, Thrombotest: a new method for controlling anticoagulant therapy, Lancet ii:754–758 (1959).
C. W. Francis, V. J. Marder, E. C. McCollister, and S. Yankoolbodi, Two step warfarin therapy, J. Am. Med. Assoc. 249:374–378 (1983).
L. Poller and D. A. Taberner, Dosage and Control of oral anticoag- ulants, An international survey, Br. J. Haematol. 51:479 (1982).
L. Poller, Standardisation of anticoagulant treatment: The Manchester Regional Thromboplastin Scheme, Br. Med. J. 2:565–566 (1964).
R. Biggs, Report on the standardisation of the one stage prothrombin time for the control of anticoagulant therapy, in: “Genetics and the interaction of blood clotting factors,” R. B. Hunter, I. S. Wright and F. Koller, eds., Thrombosis et Diathesis Haemorrhagica Supplement 17:303–327 (1965).
L. Poller, The British Comparative Thromboplastin: the use of the national thromboplastin reagent for uniformity of laboratory control of oral anticoagulants and expression of results, Assoc. Clin. Pathol., Broadsheet No.71 (1970).
J. B. Miale and J. W. Kent, Standardisation of the therapeutic range for oral anticoagulants based on standard reference plasmas, Am. J. Clin. Pathol., 60:453–457 (1972).
T. B. L. Kirkwood, Calibration of reference thromboplastins, Thromb Haemost. (Stuttgart) 49:238–244 (1983).
J. Hermans, A. M. P. H. van den Besselaar, E. A. Loeliger, and E. A. van der Veld, A collaborative calibration study of reference materials for thromboplastins, Thromb. Haemost. (Stuttgart) 50:3: 712–717 (1983).
J. M. Thomson, J. A. Tomenson, and L. Poller, The calibration of the Second Primary International Reference Preparation for Thromboplastin (Thromboplastin, human, plain, coded BCT/253), Thromb. Haemost. (Stuttgart) 52:336–342 (1984).
J. M. Thomson, K. V. Darby, and L. Poller, Calibration of BCT/44I the ICSH Reference Preparation for Thromboplastin, Thromb. Haemost. (Stuttgart) 55:379–382 (1986).
J. A. Tomenson, A statistician’s independent evaluation, in; “Thromboplastin calibration and oral anticoagulant control,” A. M. H. P. van den Besselaar, H. R. Gralnick, and S. M. Lewis, eds., Martinus Nijhoff, The Hague (1984).
R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, M. Gent, A. G. Turpie, D. McLaughlin, P. Dodd, M. Thomas, G. Rascob, and P. Ockelford, Different intensities of anticoagulation in the long-term treatment of proximal venous thrombosis, N. Eng. J. Med. 307:1676–1681 (1982).
J. Koepke, Use of survey validated plasma as a means of prothrombin time standardisation, in: “Standardisation of coagulation assays,” D. Triplett, ed., College of Clinical Pathologists, Skokie, Illinois (1982).
S. Sevitt and N. G. Gallagher, Prevention of venous thrombosis and pul- monary embolism in injured patients, Lancet ii:974–980 (1959).
J. R. A. Mitchell, Anticoagulants in coronary heart disease, Lancet i: 257–262 (1981).
J. Hilden, K. Iverson, F. Rasschon, and M. Schwarz, Anticoagulants in acute myocardial infarction, Lancet ii:327–331 (1961).
Medical Research Council, Assessment of short-term anticoagulant ad- ministration after cardiac infarction, Br. Med. J. 1:335–342 (1969).
Sixty-Plus Reinfarction Group, A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients with myocardial infarction, Lancet II:989–994 (1981).
D. W. Barrit and S. C. Jordan, Anticoagulant drugs in the treatment of thromboembolism, Lancet i:1309–13l2 (1962).
R. Hull, T. Delmore, E. Genton, J. Hirsh, M. Gent, D. Sackett, D. McLoughlin, and P. Armstrong, Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis, N. Eng. J. Med. 301:855–858 (1979).
R. Hull, T. Delmore, C. Carter, J. Hirst, E. Genton, M. Gent, J. Turpie, and D. McLoughlin, Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis, N. Eng. J. Med. 306:189–194 (1982).
S. Sevitt and D. Innés, Prothrombin time and Thrombotest in injured patients on prophylactic anticoagulant therapy, Lancet i: 124–130 (1964).
D. A. Taberner, L. Poller, R. W. Burslem, and J. B. Jones, Oral anti- coagulants controlled by British Comparative Thromboplastin versus low-dose heparin prophylaxis of deep vein thrombosis, Br. Med. J. 1:272–274 (1978).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Poller, L. (1987). INR — Calibration of the Therapeutic Range. In: Wessler, S., Becker, C.G., Nemerson, Y. (eds) The New Dimensions of Warfarin Prophylaxis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-5985-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-4757-5985-3_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-5987-7
Online ISBN: 978-1-4757-5985-3
eBook Packages: Springer Book Archive